The FDA recently approved a new drug that is supposed to slow the progression of Alzheimer’s.
Earlier this year, the FDA gave conditional approval to Leqembi, pending more safety and efficacy trials. Now, with “accelerated approval,” the drug has full approval.
Another drug, Aduhelm, launched in June 2021, still only has conditional approval and is waiting results from more trials.
Both drugs work in…